Cervical cancer vaccines: Recent advances in HPV research

Viral Immunology

Volumn 16, Issue 2, 2003, Pages 111-121

  Eiben, Gretchen L ^a   Da Silva, Diane M ^a   Fausch, Steven C ^a   Le Poole, I Caroline ^a   Nishimura, Michael I ^b   Kast, W Martin ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; PLACEBO; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR; ZYC 101A;

ADOPTIVE TRANSFER; ALPHA VIRUS; ANIMAL MODEL; ANTIGEN SPECIFICITY; BACTERIAL VECTOR; CANCER PREVENTION; CANCER RISK; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC CANCER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SEMLIKI FOREST ALPHAVIRUS; SEROCONVERSION; UTERINE CERVIX CANCER; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

ALPHAVIRUS; ANIMALIA; BACTERIA (MICROORGANISMS); DNA VIRUSES; EQUIDAE; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; SEMLIKI FOREST VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 0038043426     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/088282403322017866     Document Type: Review

References (76)

1. Adams, M., L. Borysiewicz, A. Fiander, et al. 2001. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19:2549-2556.
2. Borysiewicz, L.K., A. Fiander, M. Nimako, et al. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527.
3. Bosch, F.X., M.M. Manos, N. Munoz, et al. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Nat. Cancer Inst. 87:796-802.
4. Boursarghin, L., A. Combita, A. Touze, et al. 2002. Immunization with HPV L1 VLPs induced cross-neutralizing antibodies. Presented at the 20th International Papillomavirus Conference, Paris.
5. Boursnell, M.E.G., E. Rutherford, J.K. Hickling, et al. 1996. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14:1485-1494.
6. Breitburd, F., R. Kirnbauer, N.L. Hubbert, et al. 1995. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:3959-3963.
7. Cassetti, M., J. Pullen, S. McElhiney, et al. 2002. Development of an alphavirus replicon based vaccine for therapeutic immunization against HPV-associated cancer. Presented at the 20th International Papillomavirus Conference, Paris.
8. Centers for Disease Control. 1999. 1-1-0099.
9. Cheng, W.F., C.F. Hung, K.F. Hsu, et al. 2002. Cancer immunotherapy using Sindbis virus replicon particles encoding a Vp22-antigen fusion. Hum. Gene Ther 13:553-568.
10. Chu, N.R., H.B. Wu, T. Wu, et al. 2000. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121:216-225.
11. Clay, T.M., M.C. Custer, J. Sachs, et al. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163:507-513.
12. Coleman, N., H.D. Birley, A.M. Renton, et al. 1994. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102:768-774.
13. Cooper, L.J., M. Kalos, D.A. Lewinsohn, et al. 2000. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74:8207-8212.
14. Crish, J.F., F. Bone, S. Balasubramanian, et al. 2000. Suprabasal expression of the human papillomavirus type 16 oncoproteins in mouse epidermis alters expression of cell cycle regulatory proteins. Carcinogenesis 21:1031-1037.
15. Crum, C.P. 2002. The beginning of the end for cervical cancer? N. Engl. J. Med. 347:1703-1705.
16. Da Silva, D.M., G.L. Eiben, S.C. Fausch, et al. 2001. Cervical cancer vaccines: Emerging concepts and developments. J. Cell Physiol. 186:169-182.
17. Daemen, T., F. Pries, L. Bungener, et al. 2000. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther. 7:1859-1866.
18. Daemen, T., A. Riezebos-Brilman, L. Bungener, et al. 2003. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vac-cine 21:1082-1088.
19. Dale, C.J., X.S. Liu, R. De Rose, et al. 2002. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology 301: 176-187.
20. de Jong, A., T. O'Neill, A.Y. Khan, et al. 2002. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20:3456-3464.
21. Dupuy, C., D. Buzoni-Gatel, A. Touze, et al. 1999. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol. 73:9063-9071.
22. Durst, M., D. Glitz, A. Schneider, et al. 1992. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189:132-140.
23. Dyson, N., P.M. Howley, K. Munger, et al. 1989. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-940.
24. Eiben, G.L., M.P. Velders, and W.M. Kast. 2002. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv. Cancer Res. 86:113-148.
25. Eiben, G.L., M.P. Velders, H. Schreiber, et al. 2002. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 62:5792-5799.
26. Fausch, S.C., D.M. Da Silva, M.P. Rudolf, et al. 2002. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J. Immunol. 169:3242-3249.
27. Feltkamp, M.C., G.R. Vreugdenhil, M.P. Vierboom, et al. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:2638-2642.
28. Frisch, M., R.J. Biggar, and J.J. Goedert. 2000. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J. Natl. Cancer Inst. 92:1500-1510.
29. Harro, C.D., Y.Y. Pang, R.B. Roden, et al. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:284-292.
30. Kast, W.M. (ed.) 2000. Peptide-Based Cancer Vaccines. Eurekah.com, Austin.
31. Kaufmann, A.M., P.L. Stern, E.M. Rankin, et al. 2002. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. 8:3676-3685.
32. Kessels, H.W.H.G., M.C. Wolkers, M.D. van den Boom, et al. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2:957-961.
33. Kirnbauer, R., F. Booy, N. Cheng, et al. 1992. Papillomavirus L1 major capsid protein self-assembles into viruslike particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89:12180-12184.
34. Kiviat, N., L. Koutsky, G. Poland, et al. 2002. Long-term persistence of anti-HPV16 responses after vaccination with HPV16 L1 VLPs in initially seronegative women. Presented at the 20th International Papillomavirus Conference, Paris.
35. Klencke, B., M. Matijevic, R.G. Urban, et al. 2002. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin. Cancer Res. 8:1028-1037.
36. Koutsky, L.A., K.A. Ault, C.M. Wheeler, et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
37. Kurman, R.J., D.E. Henson, A.L. Herbst, et al. 1994. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 271:1866-1869.
38. Li, J., and A. Garen. 2002. Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. Proc. Natl. Acad. Sci. USA 99:16232-16236.
39. Lin, C.W., J.Y. Lee, Y.P. Tsao, et al. 2002. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int. J. Cancer 102:629-637.
40. Lin, K.Y., F.G. Guarnieri, K.F. Staveley-O'Carroll, et al. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21-26.
41. Liu, D.W., Y.P. Tsao, C.H. Hsieh, et al. 2000. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J. Virol. 74:9083-9089.
42. MacDonald, G.H., and R.E. Johnston. 2000. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74:914-922.
43. Michel, N., W. Osen, L. Gissmann, et al. 2002. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294:47-59.
44. Muderspach, L., S. Wilczyneki, L. Roman, et al. 2000. A phase I trial of a HPV peptide vaccine for women with high grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6:3406-3416.
45. Munoz, N. 2000. Human papillomavirus and cancer: The epidemiological evidence. J. Clin. Virol. 19:1-5.
46. Osen, W., T. Peiler, P. Ohlschlager, et al. 2001. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19:4276-4286.
47. Parkin, D.M., F.I. Bray, and S.S. Devesa. 2001. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37(Suppl 8):S4-66.
48. Pisani, P., F. Bray, and D.M. Parkin. 2002. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 97:72-81.
49. Remmink, A.J., J.M. Walboomers, T.J. Helmerhorst, et al. 1995. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer 61:306-311.
50. Ressing, M.E., A. Sette, R.M.P. Brandt, et al. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154:5934-5943.
51. Revaz, V., J. Benyacoub, W.M. Kast, et al. 2001. Mucosal vaccination with a recombinant salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 279:354-360.
52. + T-helper and a T-killer cell. Nature 393:474-478.
53. Rosenberg, S.A., J.R. Yannelli, J.C. Yang, et al. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159-1166.
54. Roszkowski, J.J., D.C. Yu, M.P. Rubinstein, et al. 2003. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J. Immunol. 170:2582-2589.
55. Schiffman, M.H., H.M. Bauer, R.N. Hoover, et al. 1993. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 85:958-964.
56. Schoenberger, S.P., R.E.M. Toes, E.I.H. Vandervoort, et al. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483.
57. Shi, W., P. Bu, J. Liu, et al. 1999. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J. Virol. 73:7877-7881.
58. + T cells. J. Immunol. 160:2896-2904.
59. Stone, K.M. 1995. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin. Infect. Dis. 20(Suppl 1):S91-S97.
60. Sun, W., L. Kuhn, T. Ellerbrock, et al. 1997. Human papillomavirus infection in women infected with the human immunodeficiency virus. N. Engl. J. Med. 337:1343-1349.
61. Suzich, J.A., S.J. Ghim, F.J. Palmer-Hill, et al. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92:11553-11557.
62. Toes, R.E.M., R. Offringa, R.J.J. Blom, et al. 1996. Peptide vaccination can lead to enhance tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855-7860.
63. Tuting, T., A. Gambotto, A. DeLeo, et al. 1999. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther. 6:73-80.
64. Urban, R.G., K. Beach, and M.L. Hedley. 2003. The clinical use of biopolymers to encapsulate and deliver pDNA-encoded antigens in cervical dysplasia patients. Presented at the 2003 Keystone Symposium, Basic Aspects of Im-munology.
65. van der Burg, S.H., K.M. Kwappenberg, T. O'Neill, et al. 2001. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine, 19:3652-3660.
66. van Driel, W.J., M.E. Ressing, G.G. Kenter, et al. 1999. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer, 35:946-952.
67. Velders, M.P., M. Markiewicz, G.L. Eiben, et al. 2003. CD4 T cell matters in tumor immunity. Int. Rev. Immunol. 22:113-140.
68. Velders, M.P., S. McElhiney, M.C. Cassetti, et al. 2001. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61:7861-7867.
69. Velders, M.P., S. Weijzen, G.L. Eiben, et al. 2001. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 166:5366-5373.
70. Villa, L., R. Costa, C. Petta, et al. 2002. A dose-ranging safety and immunogenicity study of a quadrivalent HPV (types 6/11/16/18) L1 VLP vaccine in women. Presented at the 20th International Papillomavirus Conference, Paris.
71. von Herrath, M.G., M. Yokoyama, J. Dockter, et al. 1996. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1072-1079.
72. Walboomers, J.M., M.V. Jacobs, M.M. Manos, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
73. Walboomers, J., M. Jacobs, M.M. Bosch, et al. 1999. Human papillomavirus is a necessary cause of invasive cancer worldwide. J. Pathol. 189:12-19.
74. Weijzen, S., S.C. Meredith, M.P. Velders, et al. 2001. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide. J. Immunol. 166:7151-7157.
75. Werness, B.A., A.J. Levine, and P.M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
76. Zwaveling, S., S.C. Ferreira Mota, J. Nouta, et al. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169:350-358.